Physician
Faith Medical Center P.C.
Faith Medical Center P.C. was paid $3.25M by Medicaid between Jan 2018 and Dec 2024, across 132 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 21% of everything it billed.
33Billing provider infoFAITH MEDICAL CENTER P.C.
CHARLOTTE, NC 28211
CHARLOTTE, NC 28211
33aNPI1992947766assigned 03/25/2009
33bProvider typeAddiction Medicine (Psychiatry & Neurology) Physician
28Total paid$3.25M
24GClaims172,504
24DCodes billed132
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Addiction Medicine (Psychiatry & Neurology) Physician providers in North Carolina
Rank by total paid#2 of 6
Median peer was paid$86K
This provider vs. median38×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,953 | $344K | |
| 2019 | 8,082 | $362K | |
| 2020 | 9,978 | $440K | |
| 2021 | 24,698 | $766K | |
| 2022 | 27,625 | $454K | |
| 2023 | 38,564 | $383K | |
| 2024incomplete | 52,604 | $501K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 21% | 13,666 | 8,596 | $689K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 19% | 3,681 | 2,716 | $618K |
| 99199 | Unlisted special service, procedure or report | 13% | 66,983 | 37,868 | $430K |
| 98968 | 11% | 6,946 | 1,049 | $348K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 7,883 | 5,481 | $329K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.8% | 8,393 | 5,751 | $285K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.9% | 432 | 246 | $63K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.3% | 1,962 | 1,499 | $43K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.3% | 547 | 316 | $42K |
| 86003 | 1.1% | 215 | 186 | $37K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,038 | 1,548 | $25K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 852 | 597 | $24K |
120 more codes
| 80061 | Lipid panel | <1% | 2,858 | $23K |
| 86328 | <1% | 743 | $22K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 156 | $21K |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 117 | $18K |
| 36410 | <1% | 2,568 | $17K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,708 | $16K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,379 | $16K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 95 | $13K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 125 | $12K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 136 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,930 | $10K |
| 99407 | <1% | 740 | $9K | |
| 87541 | <1% | 480 | $9K | |
| 87581 | <1% | 481 | $9K | |
| 87486 | <1% | 481 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 638 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 389 | $8K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 100 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,362 | $7K |
| 81002 | <1% | 4,561 | $6K | |
| 82948 | <1% | 4,043 | $6K | |
| 99406 | <1% | 958 | $6K | |
| 87498 | <1% | 348 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 374 | $5K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 88 | $4K |
| 92567 | <1% | 375 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 76 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 104 | $3K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 88 | $2K |
| 95923 | <1% | 63 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,157 | $2K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 32 | $2K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 133 | $2K |
| 92551 | <1% | 695 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 18 | $1K |
| 94070 | <1% | 44 | $1K | |
| 87660 | <1% | 117 | $1K | |
| 83880 | <1% | 52 | $1K | |
| 94060 | <1% | 44 | $1K | |
| 87510 | <1% | 117 | $1K | |
| 93000 | <1% | 145 | $1K | |
| 87631 | <1% | 20 | $1K | |
| 99401 | <1% | 190 | $1K | |
| 82947 | <1% | 450 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 129 | $999.57 |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 27 | $657.30 |
| 99173 | <1% | 843 | $604.55 | |
| 83874 | <1% | 52 | $525.69 | |
| 87480 | <1% | 59 | $494.80 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 23 | $486.57 |
| 87641 | <1% | 23 | $486.57 | |
| 82553 | <1% | 53 | $469.92 | |
| 87640 | <1% | 23 | $456.33 | |
| 84484 | <1% | 52 | $400.29 | |
| 85379 | <1% | 52 | $374.88 | |
| 93923 | <1% | 45 | $366.52 | |
| 88142 | <1% | 19 | $299.88 | |
| 95943 | <1% | 35 | $241.00 | |
| 80305 | <1% | 45 | $214.35 | |
| 81025 | <1% | 58 | $203.42 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 21 | $149.14 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 74 | $143.90 |
| 3044F | <1% | 402 | $100.21 | |
| 92552 | <1% | 38 | $80.75 | |
| 96127 | <1% | 26 | $65.20 | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | <1% | 791 | $51.15 |
| 99490 | Ccm add 20min | <1% | 28 | $48.60 |
| 90656 | <1% | 14 | $42.00 | |
| 90688 | <1% | 149 | $18.22 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 42 | $16.16 |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | <1% | 15 | $12.14 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 3,866 | $2.50 |
| 1160F | <1% | 1,450 | $0.29 | |
| 3074F | <1% | 2,019 | $0.28 | |
| 3079F | <1% | 1,458 | $0.26 | |
| 3077F | <1% | 1,185 | $0.21 | |
| 3078F | <1% | 1,803 | $0.20 | |
| 3080F | <1% | 878 | $0.17 | |
| 3075F | <1% | 922 | $0.13 | |
| 1159F | <1% | 160 | $0.05 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 717 | $0.00 |
| 1036F | 0% | 1,746 | $0.00 | |
| 4000F | 0% | 1,321 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 342 | $0.00 |
| 3008F | 0% | 1,217 | $0.00 | |
| 1034F | 0% | 119 | $0.00 | |
| 99000 | 0% | 198 | $0.00 | |
| 80324 | 0% | 43 | $0.00 | |
| G9902 | Patient screened for tobacco use and identified as a tobacco user | 0% | 48 | $0.00 |
| 80367 | 0% | 43 | $0.00 | |
| G9906 | Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) | 0% | 47 | $0.00 |
| 80368 | 0% | 43 | $0.00 | |
| G9903 | Patient screened for tobacco use and identified as a tobacco non-user | 0% | 55 | $0.00 |
| 80359 | 0% | 43 | $0.00 | |
| 80358 | 0% | 43 | $0.00 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 0% | 58 | $0.00 |
| 80353 | 0% | 43 | $0.00 | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 0% | 41 | $0.00 |
| 80363 | 0% | 43 | $0.00 | |
| 80349 | 0% | 43 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 2,848 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 267 | $0.00 |
| 80356 | 0% | 43 | $0.00 | |
| 80348 | 0% | 43 | $0.00 | |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 120 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 78 | $0.00 |
| 80369 | 0% | 43 | $0.00 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | 0% | 19 | $0.00 |
| 90649 | 0% | 43 | $0.00 | |
| 80354 | 0% | 43 | $0.00 | |
| 80373 | 0% | 43 | $0.00 | |
| 90658 | 0% | 15 | $0.00 | |
| G8482 | Influenza immunization administered or previously received | 0% | 18 | $0.00 |
| 80360 | 0% | 43 | $0.00 | |
| 4004F | 0% | 132 | $0.00 | |
| 80361 | 0% | 43 | $0.00 | |
| 90734 | 0% | 26 | $0.00 | |
| 80365 | 0% | 43 | $0.00 | |
| 83992 | 0% | 43 | $0.00 | |
| 80346 | 0% | 43 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialONAFOWOKAN, JOEL (MEDICAL DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Hope Mills Urgent Care & Medical Clinic, PLLC | Hope Mills, NC | $1.26M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.